J. Alper

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE

D. Wallace, S. Narain, E. Massarotti, 2019, Lupus Science & Medicine.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals

C. Cooper, D. Gladman, W. Tillett, 2012 .

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

M. Genovese, A. Kivitz, K. Jarošová, 2015, Arthritis & rheumatology.

Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID‐19 Pandemic in a Community Practice–Based Network

M. Danila, K. Saag, J. Curtis, 2021, Arthritis care & research.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.